Trial · NCT02098915
Metoclopramide Pilot Trial
NCT02098915, Phase 3, Terminated, The Hospital for Sick Children
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metoclopramide Pilot Trial. Trials, record NCT02098915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02098915
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metoclopramide Pilot Trial
- NCT number
- NCT02098915
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 10 participants, actual
- Lead sponsor
- The Hospital for Sick Children
- Conditions
- Gastroschisis
- Interventions
- intravenous metoclopramide, Placebo
- First posted
- 2014-03-28
- Last updated
- 2019-12-27
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Days to achieve full enteral feeding | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Days to achieve full enteral feeding will be recorded when all intake (at least 150 ml/kg/day for 72 hours) is given as breast milk or formula by gavage or by mouth |
| Secondary | Duration until initiation of enteral feeds | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Duration (days) until initiation of enteral feeds will be recorded |
| Secondary | Duration on parenteral nutrition | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Duration (days) on parenteral nutrition will be recorded |
| Secondary | Weight gain | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Weight gain, measured by grams per day per week during therapy will be recorded |
| Secondary | Occurrence of adverse effects | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Occurrence of adverse effects associated with the use of metoclopramide will be recorded. |
| Secondary | Rate of catheter-related sepsis episodes | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Rate of catheter-related sepsis episodes during intravenous treatment (line positive blood cultures necessitating antibiotic treatment or catheter removal) will be recorded. |
| Secondary | Incidence of necrotizing enterocolitis (NEC) | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks. Incidence of necrotizing enterocolitis (NEC) during the therapy based on clinical criteria and presence of pneumatosis intestinalis on an abdominal X-ray will be recorded. |
| Secondary | Duration of hospitalization | Participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Duration of hospitalization (number of days from admission until final hospital discharge) will be recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02098915
GET https://conductscience.org/api/trials/v1/NCT02098915/registered